Guides · PeptideU · 9 min read

Capromorelin Side Effects: What Studies Report

The short answer

Capromorelin's published safety record sits almost entirely in veterinary and animal research. Studies in dogs and cats examined daily oral administration and reported effects on body weight, food consumption and laboratory values, with tolerability observations dominated by gastrointestinal signs and hypersalivation. Additional work covers rhesus macaques, budgerigars, rat colonic transit, P-glycoprotein interaction screening and urinary detection after oral and dermal exposure. Human clinical safety trials are absent from this verified evidence base, which this page states plainly rather than filling with inference.

What this page covers

This page summarises what published studies have said about the tolerability and adverse-event profile of capromorelin, an orally active ghrelin receptor agonist. It does not teach protocols, and it does not describe how the compound is used. Readers looking for a structured introduction to the molecule, its receptor pharmacology and its research history can work through the PeptideU capromorelin course; this page stays narrowly on what the safety literature reported.

This page is for educational purposes only and is not medical advice; consult a licensed physician or an appropriately qualified veterinary professional for any question about a specific compound, patient or animal.

Where the evidence comes from

Capromorelin is a small-molecule growth hormone secretagogue that acts at the ghrelin receptor, and the review literature places its discovery, efficacy, safety and clinical applications within veterinary medicine rather than human therapeutics (PMID 37493940). A separate review described capromorelin as a ghrelin receptor agonist developed as a therapy for stimulation of appetite in dogs (PMID 29468076), and a 2025 update on clinical therapeutics in feline medicine included capromorelin among drugs discussed for cats (PMID 41051985).

Because of that history, most of what is known about adverse events comes from regulatory-style animal safety studies and veterinary clinical trials. Reviews note that the molecule reached approval as a veterinary oral solution for appetite stimulation and for weight-loss management indications (PMID 37493940).

Adverse Events in Dogs: What Studies Report

The most detailed tolerability dataset is the canine long-term safety evaluation. Researchers assessed long-term, daily oral administration of capromorelin in dogs and reported on the drug's safety profile across extended dosing, with body weight and food consumption among the outcomes tracked alongside clinical observations and clinicopathologic monitoring (PMID 27665742). That design — repeated daily exposure over many weeks with laboratory panels — is the kind of study that surfaces cumulative or delayed effects rather than only first-dose reactions.

Reviews of canine use describe the tolerability signals most often noted with the oral solution as gastrointestinal in nature, including vomiting and loose stool, together with hypersalivation after dosing (PMID 29468076). Reviews of veterinary clinical application discuss these observations in the context of the drug's appetite-stimulating mechanism, where receptor activation in the gut and stimulation of growth hormone release are the expected pharmacology rather than off-target toxicity (PMID 37493940).

Why growth hormone matters to the safety reading

Ghrelin receptor agonists raise growth hormone and, downstream, insulin-like growth factor 1, and review authors treat those endocrine shifts as part of the pharmacological profile that safety studies were designed to characterise (PMID 37493940). This is one reason long-duration studies in dogs monitored laboratory values rather than only clinical signs (PMID 27665742).

Doing the math on a vial? The PeptideU app does reconstitution, units and dilution for you.

Try it free

Adverse Events in Cats: What Studies Report

A dedicated feline safety study evaluated the safety of daily administration of capromorelin in cats, with researchers reporting the clinical observations, body weight changes and laboratory findings recorded during repeated daily dosing (PMID 29057482). As in dogs, the study structure emphasised repeated exposure over time rather than acute single-dose tolerance.

Clinical evidence in cats arrived later. A randomized, masked, placebo-controlled clinical trial examined capromorelin in cats with unintended weight loss, and researchers reported that the drug promoted weight gain in that population while adverse events occurring during the trial were recorded and compared against placebo (PMID 41204815). Placebo-controlled comparison matters for side-effect interpretation: in a sick population, vomiting, inappetence or lethargy may be features of the underlying disease rather than the drug, and only a control arm separates the two.

The 2025 feline therapeutics update discussed capromorelin among old and new drugs used in cats, placing it alongside other agents clinicians encounter (PMID 41051985).

Other species in the literature

Rhesus macaques

Researchers evaluated the safety and efficacy of capromorelin in rhesus macaques, reporting outcomes in a nonhuman primate model rather than in humans (PMID 38423529). Primate work is the closest available bridge toward human physiology in this evidence base, but it remains an animal study conducted in a laboratory-animal-medicine context.

Birds

A study in budgerigars compared the effects of capromorelin, mirtazapine and cyproheptadine on food intake, and researchers reported how the three appetite-modifying agents performed in that avian species (PMID 40638135). Cross-species comparisons like this one illustrate that response to a ghrelin receptor agonist is not uniform, which limits how far any single species' tolerability record can be generalised.

Rats and gastrointestinal motility

An earlier preclinical study reported that a ghrelin receptor agonist acted as an effective colokinetic in rats with diet-induced constipation (PMID 25616061). That finding is mechanistically relevant to the gastrointestinal observations reported in companion-animal work, because increased colonic motility and the digestive signs noted in clinical use plausibly share the same receptor pathway (PMID 29468076).

Tracking research? Log entries with dates, lots and notes — records, never plans.

Get the app

Drug interaction research: What Studies Report

Two recent papers approached capromorelin from the transporter side rather than the adverse-event side. A 2025 study assessed clinically relevant drugs as feline P-glycoprotein substrates, screening agents used in cats for interaction with the efflux transporter (PMID 41133197). A companion line of work validated a flow cytometric competitive efflux assay for assessing clinically important drugs as canine P-glycoprotein substrates (PMID 41802412). Transporter status is not an adverse event in itself, but it is the kind of pharmacokinetic property that determines whether co-administered drugs alter exposure — and therefore the likelihood of dose-related effects.

Detection after oral and dermal exposure

One analytical study addressed a different safety-adjacent question: researchers reported the detection of capromorelin in urine following both oral and dermal routes of administration (PMID 37688359). Work of this type exists largely for anti-doping and inadvertent-exposure contexts, where the question is whether a measurable urinary finding can arise from handling or contact rather than intentional ingestion (PMID 37688359).

Want the full course? Every compound, evidence-graded and cited, inside PeptideU.

Start learning free

Human safety data: a plain statement of absence

Within the verified literature summarised on this page, there are no human clinical safety trials of capromorelin. The safety evaluations are in dogs (PMID 27665742), cats (PMID 29057482, PMID 41204815), rhesus macaques (PMID 38423529), budgerigars (PMID 40638135) and rats (PMID 25616061). That absence is a finding in its own right: questions about human adverse-event rates, human drug interactions, long-term human endocrine consequences or human contraindications cannot be answered from this material. Anyone reading a confident human side-effect list for this molecule is reading something that does not come from the studies cited here.

How the reported observations compare across studies

Species / model	Study focus	What researchers reported
Dogs	Long-term daily oral administration	Safety characterised over extended daily dosing with clinical and laboratory monitoring (PMID 27665742)
Dogs	Review of appetite-stimulation therapy	Gastrointestinal signs and hypersalivation described among tolerability observations (PMID 29468076)
Cats	Daily administration safety study	Clinical observations, body weight and laboratory findings recorded during repeated dosing (PMID 29057482)
Cats	Randomized, masked, placebo-controlled trial	Weight gain reported in cats with unintended weight loss, with adverse events captured against placebo (PMID 41204815)
Rhesus macaques	Safety and efficacy evaluation	Safety and efficacy outcomes reported in a nonhuman primate model (PMID 38423529)
Budgerigars	Comparative food intake study	Effects compared with mirtazapine and cyproheptadine on food intake (PMID 40638135)
Rats	Diet-induced constipation model	Ghrelin receptor agonist reported as an effective colokinetic (PMID 25616061)
Cats and dogs (in vitro)	P-glycoprotein substrate screening	Clinically relevant drugs assessed as feline and canine P-gp substrates (PMID 41133197, PMID 41802412)

Doing the math on a vial? The PeptideU app does reconstitution, units and dilution for you.

Try it free

Reading the safety literature critically

Species is not a detail. Tolerability observed in dogs and cats does not transfer automatically to other species, a point underlined by the divergent avian comparison work (PMID 40638135).
Expected pharmacology versus toxicity. Increased food intake, motility effects and growth hormone axis changes are the intended mechanism of a ghrelin receptor agonist, and reviews frame them as pharmacology rather than as unexplained harm (PMID 37493940).
Control arms change interpretation. The masked, placebo-controlled feline trial allows drug-attributable events to be separated from disease-related ones (PMID 41204815).
Duration matters. The long-term canine study addresses cumulative exposure questions that short studies cannot (PMID 27665742).
Absence is information. No human safety trial appears in this verified set, so human adverse-event frequencies are simply unreported here.

What the literature does not establish

The studies cited here do not establish human adverse-event rates, human interaction profiles, effects in pregnancy or paediatric populations, or outcomes beyond the durations each study examined. Nor do they characterise how capromorelin behaves when combined with other compounds outside the transporter screening work described above (PMID 41133197, PMID 41802412). Where a question falls outside the scope of the published record, the honest answer is that the record is silent — not that the compound is safe or unsafe.

Tracking research? Log entries with dates, lots and notes — records, never plans.

Get the app

References

Frequently asked questions

What adverse effects have studies most often noted with capromorelin?▾

Reviews of canine clinical use describe gastrointestinal observations such as vomiting and loose stool, along with hypersalivation after oral dosing (PMID 29468076). Reviews covering veterinary applications place these within the drug's expected ghrelin receptor pharmacology rather than treating them as unexplained toxicity (PMID 37493940). Reported observations vary by species and by study design.

Are there human safety studies of capromorelin?▾

Not in the verified literature summarised here. The safety evaluations were conducted in dogs (PMID 27665742), cats (PMID 29057482), rhesus macaques (PMID 38423529), budgerigars (PMID 40638135) and rats (PMID 25616061). Human adverse-event rates, human interactions and long-term human endocrine outcomes are therefore unreported in this evidence base, and that absence should be read as absence.

What did long-term dog studies examine?▾

Researchers evaluated long-term, daily oral administration of capromorelin in dogs, characterising the safety profile across extended dosing with clinical observations, body weight, food consumption and clinicopathologic monitoring (PMID 27665742). Long-duration designs address cumulative exposure questions that short studies cannot, which is why this study forms the backbone of the canine tolerability record.

Did the placebo-controlled cat trial track side effects?▾

The randomized, masked, placebo-controlled trial in cats with unintended weight loss reported weight gain with capromorelin and recorded adverse events alongside a placebo comparison (PMID 41204815). A control arm matters because vomiting, lethargy or inappetence in a sick population may reflect underlying disease rather than the drug itself.

Why do studies mention gastrointestinal motility?▾

A preclinical study reported that a ghrelin receptor agonist acted as an effective colokinetic in rats with diet-induced constipation (PMID 25616061). That mechanism plausibly connects to the digestive observations described in companion-animal clinical use (PMID 29468076), since both involve receptor activity relevant to gut motility rather than a separate toxic pathway.

Has capromorelin been studied for drug interactions?▾

Indirectly. One study assessed clinically relevant drugs as feline P-glycoprotein substrates (PMID 41133197), and related work validated a flow cytometric competitive efflux assay for canine P-glycoprotein substrate assessment (PMID 41802412). Transporter status is a pharmacokinetic property rather than an adverse event, but it influences whether co-administered drugs change exposure.

Can capromorelin be detected after skin contact?▾

Researchers reported detection of capromorelin in urine following both oral and dermal routes of administration (PMID 37688359). Analytical work of this kind typically supports anti-doping and inadvertent-exposure investigations, where the question is whether a urinary finding could arise from contact or handling rather than deliberate ingestion.

The PeptideU app

Track it. Calculate it. Actually understand it.

Research trackerLog every entry with dates, lots and notes — records, never plans.

CalculatorsReconstitution, units and dilution maths without the guesswork.

The UniversityEvery compound explained, evidence-graded, cited to the literature.

Get started freePeptideU Premium — $9.99/mo for the full curriculum, advanced tracking & giveaways

Download on theApp Store — Free

References

18+ · Educational purposes only
This page summarises published research for education — it is not medical advice, and nothing here is a recommendation to use, purchase, or dose any substance. Study parameters described are what researchers reported, not instructions. Consult a qualified clinician before any health decision.